EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Ongoing Evaluation of Real-World Clinical Performance of a Multi-Omic Blood-Based Molecular Test (HerResolveTM) for Detection of Endometriosis in Symptomatic Women

Cory Dunn, Lori Scala, Austin Bischoff, Wing Wong, Farideh Bischoff

North American Proceedings in Gynecology and Obstetrics - Supplemental · 25.07.2026 · Suppl (MRSi)

DOI: 10.54053/001c.165357 ↗

Kurz gefasst

Fachartikel in der Zeitschrift North American Proceedings in Gynecology and Obstetrics - Supplemental, online erschienen am 25.07.2026. Verfasst von Cory Dunn und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate real-world utilization and performance characteristics of HerResolve, a multi-omic, non-invasive blood-based molecular diagnostic test, in clinically suspected endometriosis cases in a clinical setting.

Design

Retrospective observational analysis of consecutively submitted clinical cases from multiple centers across the U.S. Materials and Methods: De-identified real-world data were collected from clinical HerResolve testing performed in symptomatic women undergoing evaluation for suspected endometriosis. Clinical indications included infertility, pelvic pain, and abnormal uterine bleeding. Two datasets were analyzed: 1) Aggregate case summary dataset and 2) Patient-level dataset including demographics, biomarkers, and algorithm output probabilities. The HerResolve algorithm integrates circulating biomarkers (including microRNAs and protein markers) using a machine learning classifier (random forest-based model) to generate a prediction probability score and binary result (DETECTED vs NOT DETECTED). Descriptive statistics were used to characterize patient demographics, clinical presentation, and test result distribution.

Results

A total of 197 clinical cases were analyzed. 104 cases (53%) were Detected (positive for endometriosis) and 93 cases (47%) were Not detected. Patient Characteristics included: Mean age: 35 years; Median age: 35 years. Patients were referred for testing primarily due to infertility, pelvic pain and/or abnormal uterine bleeding. Testing was distributed across multiple ordering providers, with five centers accounting for the majority of cases reflecting broad early adoption across diverse clinical practices. Algorithm Output provided continuous prediction probabilities, demonstrating clear stratification between DETECTED and NOT DETECTED groups. High-probability outputs (>0.9) were frequently associated with DETECTED classification, supporting internal model consistency.

Conclusions

In this real-world commercial cohort, HerResolve demonstrated: 1) Clinically meaningful detection rates (~53%) in a population with suspected endometriosis; 2) Consistent performance across diverse clinical providers and indications; 3) Feasibility as a non-invasive adjunct tool in the diagnostic pathway for endometriosis. These findings support the utility of HerResolve in real-world clinical practice and highlight its potential to reduce diagnostic delays associated with invasive procedures.

Zitieren

APA

Dunn, C., Scala, L., Bischoff, A., Wong, W., & Bischoff, F. (2026). Ongoing Evaluation of Real-World Clinical Performance of a Multi-Omic Blood-Based Molecular Test (HerResolveTM) for Detection of Endometriosis in Symptomatic Women. North American Proceedings in Gynecology and Obstetrics - Supplemental, Suppl(MRSi). https://doi.org/10.54053/001c.165357

Vancouver

Dunn C, Scala L, Bischoff A, Wong W, Bischoff F. Ongoing Evaluation of Real-World Clinical Performance of a Multi-Omic Blood-Based Molecular Test (HerResolveTM) for Detection of Endometriosis in Symptomatic Women. North American Proceedings in Gynecology and Obstetrics - Supplemental. 2026;Suppl(MRSi). doi:10.54053/001c.165357

BibTeX
@article{Dunn2026,
  author = {Dunn, Cory and Scala, Lori and Bischoff, Austin and Wong, Wing and Bischoff, Farideh},
  title = {Ongoing Evaluation of Real-World Clinical Performance of a Multi-Omic Blood-Based Molecular Test (HerResolveTM) for Detection of Endometriosis in Symptomatic Women},
  journal = {North American Proceedings in Gynecology and Obstetrics - Supplemental},
  year = {2026},
  volume = {Suppl},
  number = {MRSi},
  doi = {10.54053/001c.165357}
}
Kostenlos starten →